{
  "image_filename": "figure_p10_det_9_000.png",
  "image_path": "Grohskopf_et_al.__2023_/extracted/figures/figure_p10_det_9_000.png",
  "image_type": "Figure",
  "page_number": 10,
  "block_id": "det_9_000",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A decision-tree flowchart outlining influenza vaccination dosing recommendations for children aged 6 months through 8 years based on prior vaccination status before July 1, 2022 (one dose if previously vaccinated, two doses \u22654 weeks apart if not), with accompanying text on timing and administration guidelines. does not support the claim because the figure provides dosing recommendations and timing guidelines for pediatric influenza vaccination, with no data or statements regarding recombinant vaccine technology, breadth of immune response, or cross-protection in mismatch seasons. Note: Figure is focused on vaccination schedules for children and does not address vaccine technology or immunological outcomes; no evidence of recombinant vaccine content.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A decision-tree flowchart outlining influenza vaccination dosing recommendations for children aged 6 months through 8 years based on prior vaccination status before July 1, 2022 (one dose if previously vaccinated, two doses \u22654 weeks apart if not), with accompanying text on timing and administration guidelines.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the figure provides dosing recommendations and timing guidelines for pediatric influenza vaccination, with no data or statements regarding recombinant vaccine technology, breadth of immune response, or cross-protection in mismatch seasons.",
    "confidence_notes": "Figure is focused on vaccination schedules for children and does not address vaccine technology or immunological outcomes; no evidence of recombinant vaccine content."
  }
}